RTP Mobile Logo
Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenström Macroglobulinemia
Released February 2020

Proceedings from Part 2 of a 2-part satellite symposia series during the 61st ASH Annual Meeting. Featuring perspectives from Drs Jesús G Berdeja, Sagar Lonial, María-Victoria Mateos, Nikhil C Munshi, Robert Z Orlowski and Noopur Raje. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM), Waldenström macroglobulinemia (WM) and amyloidosis.

    OVERVIEW OF ACTIVITY
    Hematologic cancers include the lymphomas, the leukemias, MM and other related disorders stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 176,200 new lymphoid, myeloid and leukemic cancer cases were identified in the United States in the year 2019, and 56,770 individuals died from these diseases. Importantly, more than 70 drug products are currently labeled for use in the management of hematologic cancers with more than 120 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology healthcare professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of their appropriate application across a vast spectrum of tumor types. This is particularly true within the realm of MM, WM and amyloidosis, where the past several years have yielded a staggering number of important clinical and research advances.

    These proceedings from a CME symposium during the ASH Annual Meeting use the perspectives of a group of community oncologists/hematologists gathered during a daylong working group to establish and subsequently address some of the most frequently encountered questions and controversies facing clinicians involved in the management of these diseases. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of MM, WM and amyloidosis with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Customize the use of induction, consolidation and maintenance therapeutic approaches for MM in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
    • Appreciate available clinical trial data documenting the efficacy of monoclonal antibody therapy directed at CD38 as a component of induction therapy, and effectively identify whether and how this strategy should be integrated into the clinical care of patients eligible or ineligible for stem cell transplant.
    • Consider published research findings and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory MM.
    • Appreciate available data documenting the activity of chimeric antigen receptor T-cell therapy, bispecific T-cell engagers and antibody-drug conjugates designed to target B-cell maturation antigen, and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches as part of a clinical trial.
    • Design and implement a plan of care for patients with smoldering MM, considering the applicability of existing and emerging clinical trial data.
    • Consider clinical and other patient-related factors in the selection and sequencing of systemic therapy for patients with WM and primary amyloidosis.
    • Assess ongoing clinical trials evaluating novel investigational approaches for MM, WM and amyloidosis, and obtain consent from appropriate patients for study participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASHMM19/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jesús G Berdeja, MD
    Director of Myeloma Research
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements: Amgen Inc, Bioclinica, Bristol-Myers Squibb Company, Celgene Corporation, CRISPR Therapeutics, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, Servier, Takeda Oncology; Contracted Research: AbbVie Inc, Acetylon Pharmaceuticals Inc, Amgen Inc, bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, Constellation Pharmaceuticals, Curis Inc, Genentech, Glenmark, Janssen Biotech Inc, Kesios Therapeutics Ltd, Lilly, Novartis, Poseida Therapeutics, Sanofi Genzyme, Takeda Oncology, Teva Oncology, Vivolux; Data and Safety Monitoring Board: Prothena.

    Sagar Lonial, MD
    Chair and Professor
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute
    Emory University
    Atlanta, Georgia

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Takeda Oncology.

    María-Victoria Mateos, MD, PhD
    Director, Myeloma Unit
    University Hospital of Salamanca
    Salamanca, Spain

    Advisory Committee: AbbVie Inc, Amgen Inc, Celgene Corporation, Genentech, GlaxoSmithKline, Janssen Biotech Inc, Mundipharma EDO GmbH, PharmaMar, Roche Laboratories Inc, Takeda Oncology; Data Monitoring Committee: Amgen Inc, Janssen Biotech Inc; Speakers Bureau: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.

    Nikhil C Munshi, MD
    Professor of Medicine, Harvard Medical School
    Director of Basic and Correlative Science
    Associate Director, Jerome Lipper Multiple Myeloma Center
    Department of Medical Oncology
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, BeiGene, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, OncoPep, Takeda Oncology; Ownership Interest: OncoPep.

    Robert Z Orlowski, MD, PhD
    Florence Maude Thomas Cancer Research Professor
    Department of Lymphoma and Myeloma
    Professor, Department of Experimental Therapeutics
    Director, Myeloma Section
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Kite Pharma Inc, Sanofi Genzyme, Takeda Oncology; Contracted Research: Amgen Inc, BioTheryX Inc, Spectrum Pharmaceuticals Inc.

    Noopur Raje, MD
    Director, Center for Multiple Myeloma
    Massachusetts General Hospital Cancer Center
    Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Merck, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP.

    CONSULTING ONCOLOGISTS/HEMATOLOGISTS — The following consulting oncologists/hematologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Warren S Brenner, MD
    Lynn Cancer Institute
    Boca Raton, Florida

    Speakers Bureau: Celgene Corporation, Takeda Oncology.

    Gautam Kale, MD, MS
    Hematology (Lead) and Oncology Staff Physician
    Cone Health Cancer Center
    Greensboro, North Carolina

    No relevant conflicts of interest to disclose.

    Khuda Dad Khan, MD, PhD
    Hematology, Oncology, Immunology
    Norton Cancer Institute
    Norton Audubon Hospital
    Louisville, Kentucky

    Consulting Agreement: Novartis; Speakers Bureau: Alexion Pharmaceuticals, Genentech, Novartis.

    Zanetta S Lamar, MD
    Florida Cancer Specialists and Research Institute
    Naples, Florida

    No relevant conflicts of interest to disclose.

    Neil Morganstein, MD
    Hematology Oncology
    Atlantic Health System
    Summit, New Jersey

    No relevant conflicts of interest to disclose.

    Namrata I Peswani, MD
    Hematology Oncology/Palliative Care
    Advocate Medical Group
    Orland Park, Illinois

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by an educational grant from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: February 2020
    Expiration date: February 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Introduction

Up-Front Management of Multiple Myeloma (MM)

Consolidation and Maintenance Therapy; Emerging Role of Minimal Residual Disease

Current Management of Relapsed/Refractory MM

Novel Strategies Under Investigation for the Treatment of MM

Therapeutic Strategies Targeting B-Cell Maturation Antigen in MM

Amyloidosis and Waldenström Macroglobulinemia (WM)

Select Publications